Hypersight and Ethos In Pediatric Radiotherapy

Recruiting now · Not applicable

Conditions studied: Cancer

In brief

This is a single-center, prospective pilot study evaluating the utility of HyperSight CBCT imaging and Ethos adaptive radiation planning in pediatric patients receiving radiation therapy for non-cranial tumors. Twenty patients aged 18 or under will be enrolled. Participants will receive standard-of-care radiation therapy, with the addition of twice-weekly HyperSight CBCT scans. These scans will be used to assess anatomical changes and generate adapted radiation plans using the Ethos platform. Radiation oncologists and radiation therapists will independently evaluate the need for adaptation, and adapted vs. scheduled plans will be compared using dosimetric and anatomical similarity metrics. An optional sub-study will allow anonymized imaging and planning data to be shared with Varian Medical Systems. The study duration will match the patient's treatment course, typically 1-6 weeks, with no additional follow-up beyond standard care.

Key facts

Study ID

NCT07528547

Run by

University Health Network, Toronto

People needed

20

Starts

2026-04-14

Expected to finish

2027-12-31

Last updated by the study team

2026-04-15

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient (paediatric or adolescent) age 18 or under receiving at least 5 days of radiation therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3

You may not qualify if…

• Patients with primary cranial tumours will be excluded due to the low expected utility of non-contrast CT scans in the delineation of brain edema and brain substructures.

Where it is running

• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.